Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Earl

Showing results (211-220 of 265) with videos related to

Pageof 27
Sort By:
Breast Cancer Research : BCR|February 18, 2016
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancerH Raza Ali, Aliakbar Dariush, Elena Provenzano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis TrialH M Earl, L Hiller, J A Dunn, et al.
Science Advances|January 31, 2025
Mechanisms of uropathogenic <i>E. coli</i> mucosal association in the gastrointestinal tractPhilippe N Azimzadeh, George M Birchenough, Nathaniel C Gualbuerto, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
The Lancet. Oncology|July 3, 2020
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trialSarah P Blagden, Adrian D Cook, Christopher Poole, et al.
Nature Communications|November 2, 2024
Distinct Escherichia coli transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selectionMark G Young, Timothy J Straub, Colin J Worby, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Distinct <i>Escherichia coli</i> transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selectionMark G Young, Timothy J Straub, Colin J Worby, et al.
The Journal of Biological Chemistry|June 11, 2020
The mitochondrial metal transporters mitoferrin1 and mitoferrin2 are required for liver regeneration and cell proliferation in miceAlexandra Seguin, Xuan Jia, Aubree M Earl, et al.
Scientific Reports|July 26, 2019
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancerSurrin S Deen, Andrew N Priest, Mary A McLean, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Pageof 27

Showing results (211-220 of 265) with videos related to

Sort By:
Pageof 27
Breast Cancer Research : BCR|February 18, 2016
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancerH Raza Ali, Aliakbar Dariush, Elena Provenzano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis TrialH M Earl, L Hiller, J A Dunn, et al.
Science Advances|January 31, 2025
Mechanisms of uropathogenic <i>E. coli</i> mucosal association in the gastrointestinal tractPhilippe N Azimzadeh, George M Birchenough, Nathaniel C Gualbuerto, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
The Lancet. Oncology|July 3, 2020
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trialSarah P Blagden, Adrian D Cook, Christopher Poole, et al.
Nature Communications|November 2, 2024
Distinct Escherichia coli transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selectionMark G Young, Timothy J Straub, Colin J Worby, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Distinct <i>Escherichia coli</i> transcriptional profiles in the guts of recurrent UTI sufferers revealed by pangenome hybrid selectionMark G Young, Timothy J Straub, Colin J Worby, et al.
The Journal of Biological Chemistry|June 11, 2020
The mitochondrial metal transporters mitoferrin1 and mitoferrin2 are required for liver regeneration and cell proliferation in miceAlexandra Seguin, Xuan Jia, Aubree M Earl, et al.
Scientific Reports|July 26, 2019
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancerSurrin S Deen, Andrew N Priest, Mary A McLean, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Pageof 27